Skip to Content

Steve Roylance has over 40 years of experience in all aspects of patent practice, from conception through patenting and enforcement, including pre-filing strategies, litigation (including jury trials), and ultimate compensation. He practices extensively before all areas of the U.S.P.T.O., with a particular focus on client counseling and strategy development.

Noteable

  • Coordinates and supervises patent prosecution in a broad spectrum of technologies, including Biotechnology, Chemical, Mechanical and Pharmaceutical areas
  • Coordinates strategy and activities in Client Counseling, Licensing and Technology Transfer, and Litigation and Trial areas
  • Lectures frequently on U.S. Patent Law in Japan

Experience

  • Owner/Manager, Patent Search Firm – 1978-1984
  • Patent Agent, Private Practice – 1984-1988
  • Patent Attorney, Private Practice, Washington, D.C. – 1988-1992
  • Patent Attorney – Greenblum & Bernstein, P.L.C. – 1992-Present

Professional Associations and Memberships

  • American Association of Pharmaceutical Scientists
  • American Bar Association
  • American Chemical Society
  • American Intellectual Property Law Association
  • Licensing Executives Society

Representative Publications

  • Roylance, S., (2020). “U.S. Supreme Court Further Strengthens IPR’s”, Journal of Generic Medicines, vol. 16, 4: pp. 171-173. First Published November 5, 2020
  • Roylance, Stephen M., (2016).  “FDA Issues Draft Guidance on Updating Labels for Generic Drugs”.  Journal of Generic Medicines, First Published September 28, 2016, (DOI: 10.1177/1741134316670698)
  • Roylance, S. (2013) “The Role of the Citizen’s Petition Amendment to the FDCA in Preventing Delays to Generic Approvals.” Journal of Generic Medicines, Pre-published online July 8, 2013 under Digital Object Identifier: 10.1177/1741134313494205
  • S., (2010). “Waiver of the Attorney – Client Privilege: Pitfalls for the Unwary.” 7 Journal of Generic Medicines 287-93.
  • Greenblum, N., Fink, M., S., Pejic, P.B., Myers-Payne, S.C., Braier, P., (2008). “Generic Drugs in a Changing Intellectual Property Landscape.” The Pharmaceutical Regulatory Process, Second Edition, pps. 143-180, Ira R. Berry and Robert P. Martin, eds., Informa Health Care
  • Braier, P., S., Greenblum. B., (2005). “U.S. Case Law Developments in 2005.” 3 Journal of Generic Medicines 237-43.
  • S., (2004). “Authorized Generics: Unlikely Alliances Yield Yet Another Controversy.” 2 Journal of Generic Medicines 71-75.